Previous studies indicated that bevacizumab is associated with a high risk of adverse events, including hypertension, proteinuria, and bleeding,[33] which is associated with its inhibitory effect on VEGF.[34,35] In general, the 2 treatment regimens showed some manageable adverse effects. This evidence concerns the gene VEGFA and hypertensive disorder.